InMode Ltd.(INMD)Earnings, Financials & Key Ratios

INMD•NASDAQ

$14.54

10.2× P/E·Price updated Jul 7, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryAesthetics, dermatology, and wound care

AboutInMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.Show more

Revenue$370M-6.2%
EBITDA$86M-24.0%
Net Income$94M-48.2%
EPS (Diluted)1.43-36.4%
Gross Margin78.54%-2.2%
EBITDA Margin23.23%-19.0%
Operating Margin23.05%-19.1%
Net Margin25.33%-44.8%
ROE13.53%-44.4%

INMD Price & Volume

InMode Ltd. (INMD) stock price & volume — 10-year historical chart

Loading chart...

Cyclical Revenue Contraction Pressures Operating Margin Efficiency

Investment Thesis • Updated 2026Q1

VerdictNeutral

Growth:Contracting

Profitability:Strained

Financial:Fortress

Cash Flow:Deteriorating

Primary Risk:Geopolitical and cyclical exposure

Key Thesis Takeaways

InMode faces a challenging transition as demand for its aesthetic platforms decelerates, evidenced by a 5.3% revenue growth rate in 2026Q1 compared to previous peak periods.
While the company maintains a fortress balance sheet with a negligible 0.01 debt-to-equity ratio, the sharp contraction in operating margins to 12.3% suggests that the current cost structure is not scaling effectively with declining sales.
Investors should monitor whether management's aggressive capital allocation, including significant historical share repurchases, can be sustained as free cash flow margins have compressed to 18.5%.

Verdict Logic

while the valuation is supported by a 10.23 P/E ratio, the ongoing volatility in net income and the compression of free cash flow margins to 18.5% warrant a cautious wait-and-see approach.

INMD Growth Metrics

InMode Ltd. (INMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years12.44%

3 Years-6.57%

TTM-4.53%

Profit CAGR

10 Years-

5 Years4.57%

3 Years-16.56%

TTM-50.4%

EPS CAGR

10 Years-

5 Years9.95%

3 Years-8.88%

TTM-41.63%

Return on Capital

10 Years34.61%

5 Years28.89%

3 Years18.57%

Last Year12.1%

INMD Recent Earnings

InMode Ltd. (INMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)

Q2 2026Latest

May 6, 2026

Metric

Actual

Est

EPS

$0.25-16.1%

$0.30

Rev

$82M+2.7%

$80M

Q1 2026

Feb 10, 2026

Metric

Actual

Est

EPS

$0.46+10.5%

$0.42

Rev

$104M+2.3%

$101M

Q4 2025

Nov 5, 2025

Metric

Actual

Est

EPS

$0.38+8.3%

$0.35

Rev

$93M+2.5%

$91M

Q3 2025

Jul 30, 2025

Metric

Actual

Est

EPS

$0.47+9.3%

$0.43

Rev

$96M-2.9%

$98M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 6, 2026	$0.25vs $0.30-16.1%	$82Mvs $80M+2.7%
Q1 2026	Feb 10, 2026	$0.46vs $0.42+10.5%	$104Mvs $101M+2.3%
Q4 2025	Nov 5, 2025	$0.38vs $0.35+8.3%	$93Mvs $91M+2.5%
Q3 2025	Jul 30, 2025	$0.47vs $0.43+9.3%	$96Mvs $98M-2.9%

Based on last 12 quarters of dataView full earnings history →

Latest INMD News

Recent stock market news and headlines for InMode Ltd. (INMD)

Business Wire·5 days ago

InMode Ltd. (INMD) Shareholders Who Lost Money – Contact Law Offices of Howard G.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of InMode Ltd. (“InMode” or the “Company”) (NASDAQ: INMD) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INMODE LTD. (INMD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@.

PRNewsWire·Jun 26, 2026

DOMA PERPETUAL CAPITAL MANAGEMENT STRONGLY OPPOSES INMODE BUYOUT AS PROPOSED; PLANS TO VOTE AGAINST DEAL

DOMA ASSERTS THAT THE $16.20 PER SHARE OFFER MATERIALLY UNDERVALUES INMODE AND ITS LONG-TERM POTENTIAL DOMA BELIEVES THE BID EXPLOITS THE DEPRESSED VALUATIONS CREATED BY YEARS OF CEO-LED UNDERPERFORMANCE DOMA EXPLICITLY REJECTS THE CURRENT TERMS AND URGES THE BOARD TO UPLHOLD ITS FIDUCIARY DUTIES MIAMI, June 26, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board").

PRNewsWire·Jun 24, 2026

InMode Confirms Receipt of Unsolicited Proposal

YOKNEAM, Israel, June 24, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) (the "Company") today announced that, on June 17, 2026, its Board of Directors (the "Board") received an unsolicited proposal from M.N.

Peers Comparison

Key metrics vs top competitors for InMode Ltd. (INMD)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
INMDInMode Ltd.Current	$14.54	$921.24M	10.17	-6.16%	25.33%	13.53%	—
AEYEAudioEye, Inc.	$7.41	$92.58M	-29.64	14.52%	-9.05%	-70.95%	—
STAASTAAR Surgical Company	$26.55	$1.32B	-16.39	-23.72%	-7.24%	-6.07%	—
NVCRNovoCure Limited	$17.72	$2.02B	-14.52	8.28%	-25.66%	-50.82%	—
ISRGIntuitive Surgical, Inc.	$427.30	$151.33B	54.29	20.51%	28.15%	16.89%	—
GMEDGlobus Medical, Inc.	$78.83	$10.63B	20.11	16.65%	18.92%	13.04%	—

Compare INMD vs Peers

InMode Ltd. (INMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AEYE

Most directly comparable listed peer for INMD.

Scale Benchmark

vs ABT

Larger-name benchmark to compare INMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs AEYE, STAA, NVCR, ISRG

Get notified when INMD posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

INMD Frequently Asked Questions

InMode Ltd. (INMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is InMode Ltd.'s revenue?

InMode Ltd. (INMD) reported $374.6M in revenue for fiscal year 2025. This represents a 1523% increase from $23.1M in 2016.

How fast is InMode Ltd. growing?

InMode Ltd. (INMD) saw revenue decline by 6.2% over the past year.

Is INMD profitable?

Yes, InMode Ltd. (INMD) is profitable, generating $87.2M in net income for fiscal year 2025 (25.3% net margin).

Dividend & Returns

What is INMD's return on equity?

InMode Ltd. (INMD) has a return on equity (ROE) of 13.5%. This is reasonable for most industries.

What is InMode Ltd.'s free cash flow?

InMode Ltd. (INMD) generated $90.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in INMD back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 6, 2026

$0.25vs $0.30-16.1%

$82Mvs $80M+2.7%

Q1 2026

Feb 10, 2026

$0.46vs $0.42+10.5%

$104Mvs $101M+2.3%

Q4 2025

Nov 5, 2025

$0.38vs $0.35+8.3%

$93Mvs $91M+2.5%

Q3 2025

Jul 30, 2025

$0.47vs $0.43+9.3%

$96Mvs $98M-2.9%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

INMDInMode Ltd.Current

$14.54

$921.24M

10.17

-6.16%

25.33%

13.53%

—

AEYEAudioEye, Inc.

$7.41

$92.58M

-29.64

14.52%

-9.05%

-70.95%

—

STAASTAAR Surgical Company

$26.55

$1.32B

-16.39

-23.72%

-7.24%

-6.07%

—

NVCRNovoCure Limited

$17.72

$2.02B

-14.52

8.28%

-25.66%

-50.82%

—

ISRGIntuitive Surgical, Inc.

$427.30

$151.33B

54.29

20.51%

28.15%

16.89%

—

GMEDGlobus Medical, Inc.

$78.83

$10.63B

20.11

16.65%

18.92%

13.04%

—